TY - JOUR
T1 - Eosinophil activation and function in health and disease.
AU - Abu-Ghazaleh, R. I.
AU - Kita, H.
AU - Gleich, G. J.
PY - 1992
Y1 - 1992
N2 - The emerging picture regarding the role of eosinophils in the immune response appears to be the following: IL-3 [in humans, (251)], and/or IL-1 [in the mouse system, (253)], then IL-5 and GM-CSF [which are secreted from activated T-cells at the inflammation sites or even from activated mast cells (346-348)] induce differentiation and proliferation of eosinophils in bone marrow. Other factors, such as PAF (303-309), C5a, soluble parasite products (259-261), or even IL-5 (139), serve as chemoattractants for eosinophils to the sites of allergic inflammation, usually around mucosal surfaces. Eosinophil survival and state of activation is enhanced by IL-5 (139). Eosinophils degranulate, thus releasing their toxic granule proteins by cross-linking Ig receptors, the most potent of which is sIgA, and the degranulation is enhanced by IL-5, IL-3, GM-CSF, and other factors or parasite products. Eosinophil degranulation can also be induced by complement, as well as PAF. The interplay of all these different mediators, and their effects on eosinophil function, is an integral part of the eosinophil's involvement in different disease conditions. Eosinophils appear to be involved in the pathophysiology of different diseases, in part, by releasing their toxic granule contents in tissues and causing tissue damage.
AB - The emerging picture regarding the role of eosinophils in the immune response appears to be the following: IL-3 [in humans, (251)], and/or IL-1 [in the mouse system, (253)], then IL-5 and GM-CSF [which are secreted from activated T-cells at the inflammation sites or even from activated mast cells (346-348)] induce differentiation and proliferation of eosinophils in bone marrow. Other factors, such as PAF (303-309), C5a, soluble parasite products (259-261), or even IL-5 (139), serve as chemoattractants for eosinophils to the sites of allergic inflammation, usually around mucosal surfaces. Eosinophil survival and state of activation is enhanced by IL-5 (139). Eosinophils degranulate, thus releasing their toxic granule proteins by cross-linking Ig receptors, the most potent of which is sIgA, and the degranulation is enhanced by IL-5, IL-3, GM-CSF, and other factors or parasite products. Eosinophil degranulation can also be induced by complement, as well as PAF. The interplay of all these different mediators, and their effects on eosinophil function, is an integral part of the eosinophil's involvement in different disease conditions. Eosinophils appear to be involved in the pathophysiology of different diseases, in part, by releasing their toxic granule contents in tissues and causing tissue damage.
UR - http://www.scopus.com/inward/record.url?scp=0026487980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026487980&partnerID=8YFLogxK
M3 - Review article
C2 - 1504137
AN - SCOPUS:0026487980
SN - 0092-6019
VL - 57
SP - 137
EP - 167
JO - Immunology series
JF - Immunology series
ER -